All news

Goldman Sachs reports a passive stake above 5% in Pacific Biosciences (PACB).

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, have reported a beneficial ownership of 23,515,936 shares, or 7.6%, in Pacific Biosciences of California, Inc. (PACB). This passive investment disclosure was made via a SCHEDULE 13G SEC filing, indicating shared voting and disposition power over the reported shares.

Read original source

PACB company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.